Eiger BioPharmaceuticals

About:

Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.

Website: http://www.eigerbio.com

Twitter/X: EigerBioPharma1

Top Investors: RA Capital Management, Vivo Capital, InterWest Partners, Pfizer Venture Investments, Oxford Finance LLC

Description:

Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.